Toutes les études
Actif, mais pas en recrutementOBSERVATIONNEL

Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency

Ornithine transcarbamylase (OTC) deficiency is a rare genetic condition where the liver cannot properly break down protein waste, causing harmful ammonia to build up in the blood. Researchers created an experimental gene therapy called DTX301 to help the liver process waste safely. This follow-up study tracks the long-term health of adults who already received a single dose of DTX301 in a previous clinical trial (Study 301OTC01). Because gene therapy is designed to have long-lasting effects, doctors need to monitor participants over time to confirm that the treatment remains safe and continues to work. Participants will not receive any new medications. Instead, they will attend regular hospital appointments for routine health checks, liver assessments, and blood tests. This information helps doctors learn more about the safety and benefits of gene therapies for people with OTC deficiency.

En un coup d'œil

Statut
Actif, mais pas en recrutement
Sponsor
Ultragenyx Pharmaceutical Inc
Objectif d'inscription
11
Démarrer
30 Aug 2018
Achèvement estimé
01 Déc 2029

De quoi parle cette étude ?

Ornithine transcarbamylase (OTC) deficiency is a rare inherited condition that affects how the body processes protein. Normally, the liver turns ammonia—a waste product of protein digestion—into a harmless chemical called urea, which leaves the body in urine. In people with OTC deficiency, the liver lacks a vital enzyme needed for this process. Without it, ammonia builds up in the blood, which can lead to severe headaches, vomiting, confusion, and even long-term damage to the brain.

To address this problem, scientists developed an experimental gene therapy called DTX301. It uses a harmless, modified virus shell to deliver a working copy of the missing gene straight into liver cells. The goal of the original treatment was to help the liver start making the missing enzyme, keeping ammonia levels safely under control.

This current study is a long-term follow-up study. It is specifically designed to keep track of participants who already received a dose of DTX301 in an earlier trial. Because gene therapies aim to create lasting biological changes, it is essential for researchers to check how patients are doing years after the initial treatment.

By taking part, participants help scientists understand both the lasting safety and the potential ongoing benefits of DTX301. The findings from this research could help improve future treatments and care for adults living with OTC deficiency across the UK and worldwide.

Points clés

  • This is a long-term safety study for adults who previously received the experimental gene therapy DTX301.
  • Only people who completed Week 52 of the previous trial (Study 301OTC01) are eligible.
  • No new medication or treatment is given; the study focuses purely on health monitoring.
  • Appointments will include routine health checks, liver assessments, and blood tests.
  • Taking part helps researchers understand the long-lasting safety and effectiveness of gene therapy for OTC deficiency.

Qui peut être éligible ?

This study is only open to adults aged 18 or older with late-onset OTC deficiency who took part in the earlier DTX301 study (Study 301OTC01) and completed their Week 52 clinic visit. If you were not enrolled in that earlier trial, you will not be able to join this study.

To be eligible, you must be willing and able to give your informed consent. You also need to be able to travel to study appointments and undergo the routine tests required by the research team.

You cannot join if you are currently taking part in another clinical trial that uses an active experimental medicine, as this could interfere with the results. You may also be excluded if you have any other significant medical condition that the study doctor feels would make taking part unsafe for you.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. I am aged 18 or older.
  2. I have been diagnosed with late-onset OTC deficiency.
  3. I took part in Study 301OTC01 and completed my Week 52 appointment.
  4. I am able and willing to attend scheduled hospital appointments for follow-up checks.
  5. I am not currently taking part in another trial testing a new medical treatment.
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

Taking part in this study does not involve taking any new medications. Instead, it involves regular follow-up visits with the study medical team over a planned period of several years. During these appointments, doctors will monitor your overall wellbeing, check your liver health, and measure the levels of ammonia and other substances in your blood. You will also be asked about any symptoms or side effects you may have experienced since your last visit. The study team will provide a schedule of visits and explain how often you will need to come to the clinic.

Risques et avantages potentiels

Taking part offers the benefit of continued, specialised medical monitoring by doctors who are experts in OTC deficiency. However, because you will not receive any new therapy, taking part may not provide any new medical improvements. The main risks involve minor discomforts from routine monitoring, such as slight bruising or soreness from blood tests, alongside the time and travel needed for hospital appointments. You are free to leave the study at any time, and doing so will not affect your normal NHS care or medical treatment.

Locations (9)

  • The Children's Hospital Colorado
    Code postal vérifié
    Aurora, États-Unis
  • Boston Children's Hospital
    Code postal vérifié
    Boston, États-Unis
  • Icahn School of Medicine
    Code postal vérifié
    New York, États-Unis
  • University Hospital Cleveland Medical Center/Case Western Reserve University
    Code postal vérifié
    Cleveland, United States
  • M.A.G.I.C. Clinic
    Code postal vérifié
    Calgary, Canada
  • Hopital Femme Mere Enfant
    Code postal vérifié
    Bron, France
  • Hospital Clinico Universitario de Santiago
    Code postal vérifié
    Santiago de Compostela, Spain
  • Hospital Universitario de Cruces. Servicio de Pediatria
    Code postal vérifié
    Barakaldo, Spain
  • Queen Elizabeth Hospital, Department of Endocrinology
    Code postal vérifié
    Birmingham, United Kingdom

Questions fréquentes

Will I receive any new gene therapy during this study?

No. This is an observational follow-up study. You will not receive any new doses of DTX301 or any other experimental medicine.

Can I join if I did not take part in the previous DTX301 study?

No. Only adults who received DTX301 in the earlier trial (Study 301OTC01) and finished their Week 52 check-up can take part.

How long will this study last?

Long-term gene therapy follow-up studies typically follow participants for several years to make sure the treatment remains safe over time. The study team will give you exact details on the timeline.

Will taking part cost me anything?

No. Study tests and visits are provided free of charge, and studies usually offer travel expense support for hospital visits.

Can I leave the study early if I change my mind?

Yes. Participation is completely voluntary. You can withdraw your consent and leave the study at any point without it affecting your standard NHS care.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.